0.0300
0.0000
(0.00%)
As of August 19 at 4:00:00 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard Jon Barry | CEO, President & Director | 7.5k | -- | 1959 |
| Mr. Eric J. Schoen | Chief Financial Officer | 460k | -- | 1968 |
| Mr. R. Christopher Cook J.D. | Senior VP, Company Secretary & General Counsel | 425k | -- | 1965 |
| Dr. James W. Kupiec M.D. | Chief Medical Officer | 435k | -- | 1954 |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | -- | -- | -- |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | -- | -- | -- |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Ms. Freda Nassif | Chief Business Officer & Chief Commercial Officer | -- | -- | -- |
| Jaren Landen | Chief Clinical Development Officer | -- | -- | -- |
Cassava Sciences, Inc.
6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
- Full Time Employees:
- 30
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Corporate Governance
Cassava Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
LIFE
ANVS Annovis Bio, Inc.
1.2850
-8.87%
AVXL Anavex Life Sciences Corp.
8.07
-2.77%
GLUE Monte Rosa Therapeutics, Inc.
3.7150
-4.50%
IKT Inhibikase Therapeutics, Inc.
1.8408
-6.79%
ABEO Abeona Therapeutics Inc.
4.4150
-10.82%
KTRA
SCPH scPharmaceuticals Inc.
2.2250
-3.27%
AXSM Axsome Therapeutics, Inc.
100.04
-7.28%
PIRS